)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Taysha Gene Therapies
Taysha Gene Therapies (TSHA) investor relations material
Taysha Gene Therapies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
TSHA-102 is in development for Rett syndrome; dosing is complete in REVEAL Part A, the 17-patient REVEAL pivotal trial and the four-patient ASPIRE trial.
All 33 treated patients cleared acute post-dose safety monitoring; no severe treatment-related serious adverse events or dose-limiting toxicities were reported as of the November 2026 cutoff.
Commercial-scale BLA-enabling PPQ met predefined specifications and comparability criteria, supporting potential inclusion of REVEAL Part A data in a BLA.
Financial highlights
Q3 2026 revenue was $0; operating expenses were $41.9M versus $34.0M in Q3 2025, and net loss was $39.1M versus $32.7M.
Q3 R&D expense was $28.8M versus $25.7M, primarily reflecting higher clinical trial and compensation costs; G&A was $13.1M versus $8.3M, including launch-readiness spending.
9M 2026 revenue was $0 versus $4.3M in 9M 2025; operating expenses were $132.7M versus $86.5M, and net loss was $128.2M versus $81.1M.
9M R&D expense rose $39.7M to $101.2M, driven by PPQ manufacturing and clinical trial costs; G&A rose $9.9M to $34.9M, including launch-readiness spending.
9M operating cash use was $114.2M; investing used $3.5M and financing provided $218.2M.
Outlook and guidance
REVEAL pivotal six-month interim topline data and FDA feedback on the potential BLA pathway are expected in H1 2027; a six-month filing could advance timing by at least two quarters versus waiting for 12-month data, subject to results and FDA feedback.
The six-month interim analysis follows the last participant reaching six months, scheduled within December; data review and FDA interaction are expected before public disclosure.
A CMC Type B meeting is planned for Q4 2026, with FDA feedback expected in Q1 2027 on PPQ results, comparability, potency-release strategy and commercial specifications.
An additional CNS gene therapy candidate nomination and preclinical development start are expected in H1 2027.
R&D and G&A spending are expected to rise with clinical development, manufacturing, precommercial and pipeline activities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Taysha Gene Therapies
- Dosing completed in pivotal trials; strong efficacy, $230M financing, and cash runway to 2028.TSHA
Q2 2026 - TSHA-102 showed 100% response and durable, multi-domain gains in Rett syndrome patients.TSHACorporate presentation
- 100% of patients showed durable, multi-domain gains and strong safety, supporting BLA plans.TSHAStudy result
- All proposals, including director elections and compensation votes, were approved.TSHAAGM 2026
- TSHA-102 pivotal trials advance with strong safety, FDA alignment, and widened Q1 2026 net loss.TSHAQ1 2026
- TSHA-102 trials progressed with strong safety, regulatory alignment, and robust cash position.TSHAQ4 2025
- TSHA-102 advanced in Rett syndrome trials, improved financials, and strong cash runway into Q4 2026.TSHAQ3 2024
- FDA alignment accelerates pivotal trial for Rett syndrome; Q1 net loss narrows, cash runway strong.TSHAQ1 2025
- TSHA-102 Phase II trials completed dosing with strong safety, narrowed net loss, and cash runway into 2026.TSHAQ4 2024
Next Taysha Gene Therapies earnings date
Q4 202623 Mar, 2027
Taysha Gene Therapies
Next Taysha Gene Therapies earnings date
Q4 202623 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Taysha Gene Therapies Inc. is a biotechnology company focused on developing gene therapies for the treatment of monogenic diseases of the central nervous system. The company leverages its adeno-associated virus (AAV) gene therapy platform to create treatments targeting rare genetic disorders, particularly those affecting the brain and spinal cord. Taysha's pipeline includes therapies aimed at conditions such as neurodegenerative and neurodevelopmental diseases, with a mission to provide life-changing treatments for patients with limited or no therapeutic options. The company is advancing its programs through research, clinical development, and regulatory processes. The company is headquartered in Dallas, Texas, and its shares are listed on the NASDAQ.